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Purpose: To highlight the pharmacology, clinical data, and practical application
for the use of insulin detemir, a new long-acting insulin analog in the treatment
of type 2 diabetes.
Data sources: Published clinical, pharmacokinetic, and pharmacodynamic
studies of insulin detemir, as well as contemporary studies and reviews about
the management of patients with type 2 diabetes.
Conclusions: Insulin therapy, if titrated appropriately, is the most physiological
and effective intervention for lowering blood glucose and may help preserve b-
cell function in patients with type 2 diabetes. Insulin detemir, in comparative
clinical trials, has been shown to provide effective glycemic control and a con-
sistent blood glucose–lowering response for up to 24 h, a decreased incidence
of nocturnal hypoglycemia, and less weight gain than other basal insulin
formulations.
Implications for practice: Insulin therapy is often met with resistance from
both patients and healthcare providers because of concerns about its effective-
ness, hypoglycemia, injections, and weight gain. Insulin detemir, designed to
closely mimic basal insulin secretion, may help overcome some of the barriers
to effective diabetes management, i.e., hypoglycemia and weight gain, and lead
to better outcomes.
Introduction
Diabetes is a major healthcare challenge for which patients
require clinical care as well as self-management education
and behavioral and emotional support. The needs of
patients with diabetes are increasingly being met by nurse
practitioners (NPs) who must remain knowledgeable not
only about the broad range of available therapies but also
about strategies to assist patients to integrate therapy into
their lifestyles and cope with the demands of this chal-
lenging chronic disease.
The American Diabetes Association (ADA) estimated
that in 2005, approximately 20.8 million people, about
7% of the U.S. population, had diabetes. Of these, 14.6
million people were diagnosed and 6.2 million remained
undiagnosed (Centers for Disease Control, 2005). Type 1
diabetes, which results from b-cell destruction and usually
leads to absolute insulin deficiency, accounts for approx-
imately 5%–10% of diagnosed cases. Gestational diabetes
includes varying levels of glucose intolerance that are
initially recognized during pregnancy. Approximately
7% of all pregnancies are affected and treatment is
required to avoid complications in the newborn. Type 2
diabetes, characterized by insulin resistance and relative
insulin deficiency, accounts for the rest, comprising the
vast majority of all diagnosed cases of diabetes in the
United States (ADA, 2004). As a result of the increased
incidence of type 2 diabetes, the responsibility for man-
agement of patients with diabetes is falling increasingly on
the shoulders of primary healthcare providers, mainly
primary care physicians, NPs, and certified diabetes
educators.
Based on information collected in the Diabetes
Prevention Program (Diabetes Prevention Program Re-
search Group, 2002), the focus of education and care for
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individuals with prediabetes is on promoting physical
activity and encouraging a healthy diet that will lead to
weight loss or at least prevent weight gain (Franz et al.,
2002). Therapeutic goals for diabetes are optimal blood
glucose and A1C targets and medical nutrition therapy to
achieve blood glucose, lipid, blood pressure, and weight
targets (ADA, 2006). For practical purposes, however,
patients are most successful when they develop their
own specific, measurable, achievable, relevant, and
time-specific behavioral goals during the course of treat-
ment (Adiseshiah, 2005). An individual’s self-selected
behavioral goals and outcomes are more likely to be
achieved if they receive ongoing support to deal with
barriers to behavior change and the emotional aspects of
having a chronic illness such as diabetes (Peyrot et al.,
2005).
Changing the paradigm of type 2
diabetes therapy
Insulin therapy is required for the treatment of type 1
diabetes because of absolute insulin deficiency; however,
the ability of people with type 2 diabetes to produce insulin
varies from person to person and changes over time.
Because of the progressive nature of type 2 diabetes, many
patients who are initially able to achieve target A1C levels
through lifestyle changes or with oral antidiabetic agents
(OADs) will eventually require insulin therapy (Diabetes
Control and Complications [DCCT] Trial Research Group,
1993; United Kingdom Prospective Diabetes Study
[UKPDS] Group, 1998).
The benefits of early insulin introduction in preserving
b-cell function are now being recognized; however, there
is still significant patient and provider resistance to initi-
ating insulin therapy (Meece, 2006; Polonsky & Jackson,
2004). The resistance can stem from a patient’s apprehen-
sion about injections, a lack of understanding about the
effectiveness and safety of insulin, fear of hypoglycemia,
feelings of failure and guilt, and concern over weight gain,
but importantly, also arises from ‘‘clinical inertia’’ and
prescribing attitudes of healthcare providers about insulin
therapy (Perlin & Pogach, 2006; Peyrot et al., 2005). The
Diabetes Attitudes Wishes and Needs (DAWN) study,
a large multinational survey examining patient and pro-
vider perceptions to insulin therapy, found that 51% of
nurses, 60% of primary care physicians, and 52% of
specialists admitted to always or often warning patients
that they would have to start on insulin therapy if they did
not follow lifestyle recommendations (Korytkowski,
2002). Rather than approaching insulin therapy as a threat
or a ‘‘last resort,’’ practitioners are beginning to see insu-
lin in a new light because therapy with insulin is ‘‘phys-
iological,’’ effective, and beneficial for patients who are
trying to achieve glycemic goals (Funnell & Kruger, 2004;
Stoneking, 2005).
Treatment of diabetes, including helping patients suc-
cessfully transition to insulin therapy, requires creating
a partnership with patients where both the expertise of the
nurse and the opinions and fears of the patient are equally
valued (DCCT Research Group, 1993; Funnell, Kruger, &
Spencer, 2004; UKPDS Group, 1998). To help ease the
transition, new technological advances are now available,
including more user-friendly blood glucose monitoring
systems, comfortable and easy-to-use insulin pen devices,
and an increasing number of insulin analogs.
There are more options than ever before to initiate
insulin therapy. For example, premixed biphasic insulin
analog formulations are one option for initiating insulin
among patients with type 2 diabetes (Garber, 2006). These
premixes, insulin lispro 75/25 (75% insulin lispro prot-
amine suspension and 25% insulin lispro) and biphasic
insulin aspart 70/30 (70% insulin aspart protamine sus-
pension and 30% insulin aspart), offer patients the sim-
plicity of once- or twice-daily dosing combined with rapid
onset of action to cover prandial insulin needs, prolonged
action to cover basal insulin needs, and the reduced
variability of an analog compared with a human insulin
premix (Garber).
Another common and simple regimen for initiating
insulin in patients with type 2 diabetes involves the use
of a basal or long-acting insulin analog alone or in com-
bination with OADs. With a prolonged duration of action
and relatively peakless action profile, basal insulin analogs
offer once-daily dosing and a low risk of hypoglycemia. At
present, there are two long-acting insulin analogs that
have been developed for use as the basal component of
insulin therapy: insulin glargine and insulin detemir.
Insulin detemir, the newest of these, has been used in
Europe for several years. Having received Food and
Drug Administration approval in June 2005 for use in
the United States, insulin detemir is highlighted in this
review, with its usefulness placed into context for NPs,
diabetes educators, and other practitioners who are the
main sources of care and education for their patients with
diabetes.
Pharmacology of insulin detemir
Insulin detemir is an analog of human insulin with
a 14-carbon fatty acid chain attached to the lysine residue
on position 29 of the insulin B chain (Vazquez-Carrera &
Silvestre, 2004). The addition of the fatty acid chain on
insulin detemir promotes increased self-association of
insulin detemir molecules and allows for the reversible
binding of insulin detemir to albumin at the injection site,
contributing to its novel mechanism for protracted action
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(Chapman & Perry, 2004; Novo Nordisk, 2005). Insulin
detemir molecules can readily enter the circulation, where
they again reversibly bind albumin, further delaying dis-
tribution to target tissues (Hordern & Russell-Jones, 2005).
Insulin detemir is soluble at neutral pH, which enables it
to exist as a liquid following subcutaneous injection. This is
different from neutral protamine hagedorn (NPH)—the
traditional human intermediate acting formulation—
which is a preformed crystalline/precipitate suspension,
and insulin glargine, an acidic solution that precipitates
at pH 7.0 in the subcutaneous tissue after injection
(Chapman & Perry, 2004). Because precipitation and dis-
solution of a precipitate upon injection contribute to
variability in absorption of insulin, the solubility of insulin
detemir is likely a factor that reduces within-patient var-
iability and provides more predictable glycemic control
compared with NPH insulin or insulin glargine (see below)
(Heise et al., 2004).
Pharmacodynamics and pharmacokinetics
of insulin detemir
Insulin detemir has a relatively flat time-action profile
with a duration of action of up to 24 h (Klein et al., 2006;
Novo Nordisk, 2005; Plank et al., 2005). With its fatty acid
modification, insulin detemir is less susceptible to the
variability in action that occurs with other basal insulin
preparations. Several important factors contribute to its
consistent activity: (a) insulin detemir is water soluble and
resuspension is not required prior to injection, (b) insulin
detemir remains in solution upon injection, and (c) revers-
ible albumin binding buffers the effect of sudden changes
in the depot absorption rate. In studies of the pharmaco-
dynamics of insulin in patients with type 1 diabetes (mea-
sured by the rate that glucose must be infused to maintain
stable glucose levels), insulin detemir was associated with
significantly less within-patient variability than NPH insu-
lin or insulin glargine (Heise et al., 2004; Klein et al.).
Similarly, patients with type 2 diabetes treated with insulin
detemir plus insulin aspart at mealtimes showed signifi-
cantly lower within-patient variability of self-measured
blood glucose compared with patients treated with NPH
insulin (Haak, Tiengo, Draeger, Suntum, & Waldhausl,
2005). The shapes of the glucose infusion rate curves in
patients with type 2 diabetes receiving either insulin dete-
mir or insulin glargine are similar, with comparable dura-
tions of action up to 24 h at clinically relevant doses
(Klein et al.).
When administered as a single dose to healthy volun-
teers, insulin detemir shows a linear and dose-dependent
plasma concentration profile, with the maximum concen-
tration (Cmax) reached between 6 and 8 h (Novo Nordisk,
2005). The distribution of insulin detemir is dominated by
a high percentage bound to albumin in the bloodstream.
Despite this high level of albumin binding, insulin detemir
is not likely to be involved in competitive drug interactions
at the albumin-binding site (Chapman & Perry, 2004), as
there is a vast excess of albumin-binding sites available to
each drug molecule. The pharmacokinetics of insulin
detemir are similar in children and adults (Danne, Lupke,
Walte, Von, & Gall, 2003), and there are no differences in
patients of different race or ethnicity (Chapman & Perry;
Soran & Younis, 2006; Troupin et al., 2005). Dosing,
administration, availability, and storage information
about insulin detemir are summarized in Table 1. Insulin
detemir is available in easy-to-use pen injection devices,
whicharediscrete, convenient, andcan increase apatient’s
confidence levels with regard to performing self-injections
(Korytkowski, Niskanen, & Asakura, 2005). As with other
injectable insulin formulations, minor local reactions
around the injection site have occasionally been reported
with insulin detemir (Hermansen et al., 2004; Raslova
et al., 2004). Suggested management of injection site dis-
comfort includes careful cleansing of the skin with a non-
irritant solution, rotating injection sites within a given
area, and the use of antihistamine creams to reduce dis-
comfort (Jordan & Lake, 2005).
Overcoming barriers associated with
insulin therapy
Despite evidence supporting the importance of glycemic
control (Stevens et al., 2004; UKPDS Group, 1998), in
practice, recommended glycemic targets are often not met.
Data from a recent update of the National Health and
Nutrition Examination Survey indicate that only 42% of
adults had A1C values less than 7% (ADA goal) and one in
five still have A1C levels of 9% or higher (Saaddine et al.,
2006). Clinical inertia on the part of healthcare providers
to change practice patterns, despite the known benefits of
aggressive treatment, is now recognized as a part of the
problem (Perlin & Pogach, 2006). In addition, glycemic
targets are often considered too difficult for patients to
attain and can result in poor motivation for providers and
patients because of perceived failure (Hainsworth, 2005).
NPs can help patients with diabetes to understand the
natural progression of the disease and why different ther-
apies are needed over the course of the disease (Funnell
et al., 2004). They can also help patients to understand
diabetes as an ‘‘insulin problem’’ rather than a ‘‘sugar
problem,’’ assess fears and barriers regarding insulin ther-
apy, and assist patients to identify and address those issues
(Meece, 2006).
Patient concerns that serve as barriers to initiation
include perceived injection pain, lack of understanding
about proper injection technique and timing, and fear of
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hypoglycemia, weight gain, or disease progression
(Korytkowski, 2002). Results from the DAWN study tell
us that patients may not believe that insulin is effective,
and self-blame among patients with type 2 diabetes is
prevalent and associated with worry about starting insulin
therapy. Individuals may express feelings of guilt and
failure as they may consider insulin therapy to be the
result of their inability to achieve their glycemic target
through diet or exercise (Korytkowski). To prevent patient
anxiety, it is recommended that NPs avoid the use of
insulin as a threat or punishment in an effort to encourage
better self-care (Peyrot et al., 2005). Instead, the focus
should be placed on how insulin will help patients achieve
their self-identified goals and targets and incorporate dia-
betes into their lives.
Teaching patients from the onset of diabetes about the
use of insulin as a ‘‘next step’’ in therapy can help to
prevent some feelings of guilt, as does avoiding phrases
such as ‘‘you failed oral agents.’’ Minimizing the number of
injections, using insulin pens, discussing the relative risks
of hypoglycemia, and asking patients to identify personal
benefits associated with lower glucose levels (i.e., more
energy) and how their goals may be achieved with insulin
therapy are several recommended interventions to over-
come patient concerns (Funnell & Kruger, 2004; Polonsky
& Jackson, 2004).
Concerns surrounding insulin therapy are not limited to
patients. Healthcare providers have reported fear of
patients’ anger, fear of patients’ noncompliance, and irri-
tation with OAD failure (Korytkowski, 2002). According
to the DAWN study, general practitioners were more likely
to delay insulin therapy than specialists, opinion leaders,
and healthcare providers who treat many patients with
type 2 diabetes. Prescribing insulin was more likely to be
delayed when nurses and physicians viewed insulin as
a less effective treatment (Peyrot et al., 2005). Thus, it is
important to not only be aware of newer insulin therapies
but also to create systems of care that support both the
efforts of patients and the NPs to effectively use those
therapies.
How insulin detemir can help overcomebarriers
to initiating insulin therapy
Insulin detemir has been shown to be as effective or
more effective than NPH insulin and insulin glargine in
maintaining glycemic control (Dornhorst, Merilainen, &
Ratzmann, 2006b; Haak et al., 2005; Hermansen et al.,
Table 1 Insulin detemir dosing, administration, availability, and storage (Novo Nordisk, 2005)
Dose The dosage of insulin detemir should be individualized according to the patient’s needs,
with the following suggestions to be used as a guide:
l For insulin-naı̈ve patients who are not achieving glycemic goals on OADs
—Start with either 0.1 or 0.2 units/kg or 10 units once daily at the evening mealtime or bedtimea
—Titrate graduallyb (upward or downward) to achieve desired glycemic goals
—For patients who require twice-daily insulin dosing for effective control, the evening dose can be
administered with the evening meal, at bedtime, or 12 h after the morning dose
l Patients already treated with a basal insulin can transition to insulin detemir on a unit-to-unit basis
Route of administration l Subcutaneously in thigh, abdominal wall, or upper arm
Mixing l Because of pH differences that could affect the action profile and efficacy of each, insulin detemir
should not be mixed with other insulins
Availability l 3 mL prefilled FlexPen (100 units/mL)
l 10 mL vials (100 units/mL)
Storage l Unopened vials and FlexPen can be stored at room temperature for 42 days or in the refrigerator
until the expiration date
l Once in use, vials can be used for 42 days and be kept at room temperature or refrigerated.
Once in use, the FlexPen should be kept at room temperature and can be used for 42 days
l Never freeze preparations of insulin detemir; preparations that have been inadvertently frozen
should be discarded
l Refer to the manufacturer’s instructions for further information about storage and handling
aIn a treat-to-target trial (Hermansen et al., 2006), insulin (10 units/injection) was added to oral glucose-lowering drugs (metformin, insulin secretagogues,
or a-glucosidase inhibitors).
bIn the same treat-to-target trial, daily self-monitored plasma glucose values were averaged over three consecutive days. Corresponding to individualized
elevated plasma glucose readings, insulin doses were adjusted upward in 2- to 10-unit increments in a sliding scale algorithm. For example, if average
prebreakfast/predinner readings were 109–126 mg/dL, 145–162 mg/dL, or >180 mg/dL, insulin dose increases of +2, +4 to +6 units, or +10 units,
respectively, were recommended (Hermansen et al., 2006). If plasma glucose readings were low after one reading, i.e., 56–72 mg/dL or <56 mg/dL,
decreases in insulin doses by 2–4 units/injection were implemented, respectively.
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2004, 2006; Home et al., 2004; Raslova et al., 2004;
Rosenstock et al., 2006; Russell-Jones, Simpson, Hylleberg,
Draeger, & Bolinder, 2004). In addition to efficacy, other
clinically relevant characteristics of insulin detemir
(i.e., low risk of hypoglycemia, less within-patient vari-
ability, and a reduced tendency to cause weight gain) make
it a good option for practitioners and patients who are
considering initiating insulin therapy (Chapman & Perry,
2004).
Clinical effectiveness
The clinical efficacy and tolerability of insulin detemir
have been most commonly compared with NPH insulin.
The major efficacy endpoint in these trials is glycemic
control, typically monitored by A1C levels and fasting blood
glucose (FBG), as well as the incidence of hypoglycemia.
Several studies in patients with type 2 diabetes have
demonstrated the efficacy of insulin detemir. The first to
report comparative results to NPH was conducted in 505
individuals randomly assigned to NPH insulin or insulin
detemir as part of a basal–bolus therapy. Rapid-acting
insulin aspart was used at mealtimes. In this 6-month
study, overall blood glucose control was not different
between insulin detemir and NPH insulin (Haak et al.,
2005). However, treatment with insulin detemir resulted
in less within-participant variability in FBG compared with
NPH insulin (Haak et al.). Studies of the pharmacodynamic
properties of insulin detemir have shown reduced intra-
and interpatient variability in FBG compared with NPH
insulin (Heise et al., 2004; Hermansen et al., 2004; Pieber,
Draeger, Kristensen, & Grill, 2005). Differences in within-
patient variability were substantiated in patients with type
2 diabetes in a study comparing insulin detemir with NPH
insulin (Raslova et al., 2004). In another study in which
insulin detemir and NPH insulin were added to OAD
therapy, more than 70% of patients in both groups
achieved an A1C of 7% or lower. However, a significantly
greater percentage of patients treated with insulin detemir
reached this goal without any hypoglycemia compared
with patients on NPH insulin (26% vs. 16%, p < .01)
(Hermansen et al., 2006). Finally, in a study setting that
reflects actual clinical practice with type 2 diabetes
patients, adding basal insulin detemir to OADs reduced
A1C by 1.29% and FBG by 58 mg/dL over 3 months and
did so with an average reduction in weight of 0.9 kg and
fourfold fewer hypoglycemic episodes than previous ther-
apy (Dornhorst, Merilainen, & Ratzmann, 2006a).
Insulin detemir has also been extensively studied in
patients with type 1 diabetes. Over 11 randomized trials
using both once- and twice-daily regimens of insulin
detemir have compared its efficacy to either NPH insulin
or insulin glargine (Home & Kurtzhals, 2006). In one 4-
month study, patients who received twice-daily insulin
detemir (either at 12-h intervals or at morning and bed-
time) or NPH insulin (morning and bedtime) with rapid-
acting insulin aspart at mealtimes (Home et al., 2004) had
significantly lower FBG when treated with insulin detemir
compared with NPH. Within-participant variability in self-
monitored FBG was also significantly lower in the insulin
detemir treatment groups (Home et al., 2004). In a 6-
month trial comparing once-daily insulin detemir or
NPH insulin in combination with regular human insulin
(Russell-Jones et al., 2004), analysis of self-monitored FBG
readings showed significantly less variability during treat-
ment with insulin detemir than with NPH insulin.
Hypoglycemia
Considerable risk of mild-to-severe hypoglycemia can
be associated with any insulin therapy (Davis & Alonso,
2004), and the challenges of managing hyperglycemia
must be balanced against the risk of hypoglycemia. Fear
of hypoglycemia is often identified as a barrier (Cryer,
Davis, & Shamoon, 2003), particularly among patients
who worry that it will be a threat to their independence.
Providers are concerned about hypoglycemia as well,
explaining, at least in part, why glycemic targets are not
achieved. For example, in one treat-to-target study, the
most common reason that clinicians chose not to titrate
insulin doses upward was related to concern over hypo-
glycemia (Fritsche, Haring, Togel, & Schweitzer, 2003).
If fear of hypoglycemia is identified as a barrier, the
healthcare provider should first assess the source of the
fear and then provide support as needed. Strategies for
dealing with hypoglycemia include education about the
usefulness and frequency of blood glucose monitoring and
ensuring that patients are aware of warning signs, risk
factors, and how to self-treat hypoglycemia (Jordan &
Lake, 2005). It may be helpful to point out that hypogly-
cemia is more common in patients with type 1 than with
type 2 diabetes (Cryer et al., 2003) and that the newer long-
acting insulin analog preparations are less likely to cause
hypoglycemia than the older, less predictable preparations.
The relatively flat time-action profile and consistent
blood glucose–lowering response of insulin detemir results
in reduced incidence of hypoglycemia when compared
with NPH insulin (Heller & Kim, 2005; Hermansen et al.,
2004, 2006; Home et al., 2004; Russell-Jones et al., 2004).
In a 4-month trial of patients with type 1 diabetes ran-
domly assigned to receive twice-daily insulin detemir or
NPH insulin, insulin detemir was associated with a signif-
icant reduction in the risk of minor hypoglycemia (25%–
32%) compared with NPH insulin (Home et al.). Observing
patients with type 2 diabetes treated with or without OADs
who switched to insulin detemir from previous therapy
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with NPH or insulin glargine, the risk of hypoglycemia was
reduced from 7.9 to 1.5 episodes and from 7.8 to 0.5
episodes per patient-year, respectively (Dornhorst et al.,
2006b). A meta-analysis of four phase 3 trials with insulin
detemir concluded that the reduction in intrapatient var-
iability of FBG is a major contributor to the reduced risk of
hypoglycemia with insulin detemir relative to NPH insulin
(Heller & Kim, 2005).
Nocturnal hypoglycemia often goes unrecognized
because patients may not awake from symptoms, it is
not readily self-treated, and it may be prolonged. Thus,
nocturnal hypoglycemia poses special safety risks, includ-
ing falls, adds to patient fears, and presents a barrier to
insulin use. Reductions in the incidence of nocturnal
hypoglycemia have also been demonstrated in patients
who use detemir. For example, in trials comparing twice-
daily insulin detemir to NPH insulin, in patients with type 1
or type 2 diabetes, the incidence of nocturnal hypoglyce-
mic episodes was 53%–55% lower with insulin detemir
than with NPH (Hermansen et al., 2004, 2006; Home et al.,
2004). Once-daily insulin detemir also reduced the risk of
nocturnal hypoglycemia by 26% compared with once-
daily NPH insulin (p = .003), with comparable reductions
in A1C (Russell-Jones et al., 2004). Compared with insulin
glargine in patients with type 1 diabetes, insulin detemir
resulted in a lower risk of major and nocturnal hypogly-
cemia at comparable levels of glycemic control (Pieber,
Treichel, Robertson, Mordhorst, & Gall, 2005). A lower
risk of hypoglycemic episodes with insulin detemir and
therefore a reduction in the fear of such episodes may
make patients less likely to skip injections.
Weight gain
Another barrier to insulin therapy commonly identified
by patients with type 2 diabetes is weight gain. Although
the cause of weight gain associated with insulin or other
diabetes therapies is not completely understood, weight
gain may result from better glucose control (Fritsche &
Haring, 2004). As blood glucose levels fall, the amount of
glucose excreted in the urine also falls, and patients may
not adequately decrease caloric intake to compensate for
the calories lost in the urine (Bode, 2004; DeWitt & Hirsch,
2003; Klingensmith, 2003; Sheehan, 2003). Some clini-
cians have speculated that weight gain may also be linked
to the need to ‘‘feed the insulin’’ to prevent hypoglycemia,
particularly when older preparations of insulin are used
and/or patients’ fear of hypoglycemia (Klingensmith;
Sheehan).
To date, all studies conducted with insulin detemir in
which weight was evaluated, in patients either with type 1
(Hermansen et al., 2004; Home et al., 2004; Pieber,
Draeger, et al., 2005; Russell-Jones et al., 2004) or with
type 2 diabetes (Haak et al., 2005; Hermansen et al., 2006;
Raslova et al., 2004), have consistently shown less weight
gain in comparison to NPH insulin. One study of once-
daily insulin detemir in patients with type 1 diabetes found
that patients lost a mean of 0.50 lb during the 6-month
trial, whereas those treated with NPH insulin showed
a mean weight gain of 0.70 lb (Russell-Jones et al.).
Similarly, data from studies in patients with type 2 diabetes
show that treatment with insulin detemir results in less
weight gain compared with NPH insulin. A recent study
comparing the addition of insulin detemir or insulin glar-
gine to OADs also found significantly less weight gain with
insulin detemir (Rosenstock et al., 2006). The lack of
weight gain with insulin detemir may be, in part, because
of decreased within-patient variability and a reduction in
the perceived risk of hypoglycemia (Haak et al.; Russell-
Jones et al.). However, the mechanisms behind the favor-
able weight effects of insulin detemir are not fully under-
stood and are still being investigated (Hennige et al., 2006;
Hordern & Russell-Jones, 2005).
Summary
The newer long-acting insulin analog, insulin detemir, is
an excellent option for patients with diabetes who need
a basal insulin replacement that closely mimics physiolog-
ical basal insulin release. In comparative trials with other
basal insulin preparations, insulin detemir has been shown
to improve glycemic control with decreased within-patient
variability, decreased incidence of hypoglycemia, includ-
ing nocturnal hypoglycemia, and less weight gain. Given
that the most difficult part of initiating insulin therapy
often is overcoming patient and provider fears leading to
clinical inertia, the availability of insulin detemir may help
alleviate some of this difficulty and improve outcomes for
patients with type 2 diabetes.
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